Eric Lefkofsky

Eric Lefkofsky started his career by selling carpets at the University of Michigan. Eric Lefkofsky is the co-founder and CEO of Tempus, a startup company that built an operating system to advance the treatment of cancer. He is also the chairman of Groupon and Uptake Technologies. He has also a trustee at Lurie children’s hospital in Chicago.

Cancer is an abnormal cell growth with the potential to spread to other parts of the body. In 2015 about 90.5 million people suffered from cancer. Cancer’s burden in society has become vast enough so that almost every person either knows or is related to someone who has suffered from cancer.

According to Eric Lefkofsy, Tempus is an end-to-end solution. His objective is to collect huge amounts of data through its collaborations with academic institutions and hospitals. Its services are two-fold, namely to provide gene-sequencing tests at its River North headquarters in a laboratory, and to provide physicians software-based solutions that give a rapid comparison of a patient’s genetic profile to its database.

Lefkofsky also serves as a Trustee of Lurie Children’s Hospital situated in Chicago, The Art Institute of Chicago, World Business Chicago and The Museum of Science and Industry.

Tempus has developed an operating system or software data platform providing analysis of large volumes of clinical and molecular data. It is working with systems of hospitals such as Northwestern, the University of Michigan, the Mayo Clinic, the Cleveland Clinic, the UC Davis Comprehensive Cancer Center and Duke University School of Medicine.

The Tempus website shows it has helped doctors and professionals of health care, make decisions based on the data they have gathered. Tempus also says it has been using “cutting-edge genomic sequencing and analysis methods” and helping doctors for a better understanding of patient’s cancer.

Tempus founded in 2015, has since grown to a 200 employee company and is one of the top ten Chicago tech startups. Tempus shares the ranking with companies such as Avant, Outcome Health, SMS Assist, IRI, SpringCM and Analyte Health. Recently Tempus has secured about $70 million in funding and which it has used to provide services to patients.